19 June 2024 in npj Precision Oncology
HMHécTor MartínEz-Gregorio
HécTor MartínEz-Gregorio
CDClara Estela DíaZ-VelásQuez
Clara Estela DíaZ-VelásQuez
NRNorma Gabriela Resendiz-Flores
Norma Gabriela Resendiz-Flores
+10
Less than 15–20% of patients who meet the criteria for hereditary breast and ovarian cancer (HBOC) carry pathogenic coding genetic mutations, implying that other molecular mechanisms may contribute to the increased risk of this condition. DNA methylation in peripheral blood has been suggested as a potential epigenetic marker for the risk of breast cancer (BC). We aimed to discover methylation marks in peripheral blood associated with BC in 231 pre-treatment BC patients meeting HBOC criteria, testing negative for coding pathogenic variants, and 156 healthy controls, through methylation analysis by targeted bisulfite sequencing on 18 tumor suppressor gene promoters (330 CpG sites). We found i) hypermethylation in EPCAM (17 CpG sites; p = 0.017) and RAD51C (27 CpG sites; p = 0.048); ii) hypermethylation in 36 CpG-specific sites (FDR q < 0.05) in the BC patients; iii) four specific CpG sites were associated with a higher risk of BC (FDR q < 0.01, Bonferroni p < 0.001): cg89786999-FANCI (OR = 1.65; 95% CI:1.2–2.2), cg23652916-PALB2 (OR = 2.83; 95% CI:1.7–4.7), cg47630224-MSH2 (OR = 4.17; 95% CI:2.1–8.5), and cg47596828-EPCAM (OR = 1.84; 95% CI:1.5–2.3). Validation of cg47630224-MSH2 methylation in one Australian cohort showed an association with 3-fold increased BC risk (AUC: 0.929; 95% CI: 0.904–0.955). Our findings suggest that four DNA methylation CpG sites may be associated with a higher risk of BC, potentially serving as biomarkers in patients without detectable coding mutations.
2 July 2025 in Briefings in Bioinformatics
Motivation: Bisulfite sequencing (BS-Seq) enables a comprehensive and detailed analysis of DNA methylation patterns at single-nucleotide resolution. While methylation differences can contribute to various diseases, their sincronous occurrence at distinct loci complicates understanding. Therefore, advanced tools are essential to facilitate the identification and analysis of methylation programs and patterns. Results: AutoMethyc provides a comparative approach by integrating different algorithms coordinated and optimized for use on desktop computers and servers. The workflow evaluates the methylation status from different perspectives, facilitating interpretation in an interactive HTML report, incorporating new co-methylation analyses for marker identification, as well as exploratory complex workflows with dimension reduction techniques and identification of unsupervised groups between samples or sites. AutoMethyc was tested in a breast cancer study ($n=389$; 233 cases and 156 controls) using BS-Seq data from the Illumina MiSeq platform, mapping 330 methylation-prone citocine (CpG) sites in 20 genes. The analysis was performed on a desktop with 64 GB RAM, 16 cores (4.673 GHz), and 326 KB/s internet, running Fedora 39 with i3wm. The tool processed the dataset in 48 h, showcasing its efficiency and scalability.